TIMP2 and ovarian carcinoma: We have previously described the reduction or knock down of TIMP-2 expression in ovarian cancer cell lines (OVCAR4, JOSH2, FT282) by using three distinct 27mer siRNA duplexes independently, or a pooled (A + B + C) siRNA duplexes directed against human TIMP-2 (T2-KD cells) [24].